CytomX Income Quality from 2010 to 2024

CTMX Stock  USD 0.89  0.02  2.30%   
CytomX Therapeutics Income Quality yearly trend continues to be fairly stable with very little volatility. Income Quality is likely to outpace its year average in 2024. Income Quality is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. View All Fundamentals
 
Income Quality  
First Reported
2010-12-31
Previous Quarter
98.4797891
Current Value
103.4
Quarterly Volatility
35.48405373
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0299 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CytomX Therapeutics Correlation against competitors.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Latest CytomX Therapeutics' Income Quality Growth Pattern

Below is the plot of the Income Quality of CytomX Therapeutics over the last few years. It is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. CytomX Therapeutics' Income Quality historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Quality10 Years Trend
Slightly volatile
   Income Quality   
       Timeline  

CytomX Income Quality Regression Statistics

Arithmetic Mean13.63
Coefficient Of Variation260.34
Mean Deviation23.28
Median0.53
Standard Deviation35.48
Sample Variance1,259
Range107
R-Value0.59
Mean Square Error877.99
R-Squared0.35
Significance0.02
Slope4.71
Total Sum of Squares17,628

CytomX Income Quality History

2024 103.4
2023 98.48
2022 1.12
2021 1.42
2020 -0.16
2019 1.37
2018 0.89

About CytomX Therapeutics Financial Statements

CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Income Quality, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Quality 98.48  103.40 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.